Molecular Biosystems steps up the fight to protect Optison
This article was originally published in Clinica
Executive Summary
Molecular Biosystems (MBI) has asked the US Patent Office to reconsider the patent grant to Nycomed Imaging, asserting that previous mentions in scientific literature of the use of perfluorocarbons invalidated Nycomed's claims to patentability.